Eli Lilly Gene-Editing Therapy Reduces Cholesterol by 62% in Phase 1 Trial

Eli Lilly announced on May 25, 2026, that a high dose of its gene-editing therapy, VERVE-102, reduced cholesterol levels by 62% in participants during a Phase 1 clinical trial. The results provide early evidence that a one-time treatment could eventually serve as a viable option for individuals seeking to lower their LDL, or bad, cholesterol.

The therapy is designed to provide a permanent reduction in cholesterol, contrasting with conventional treatments that require daily or periodic administration. Company executives have described the therapy as a potential method to broadly prevent heart disease, which remains the leading cause of death globally.

Safety Results and Clinical Progress

A primary focus of the Phase 1 study was the safety profile of the gene-editing candidate. According to the company, there were no treatment-related serious adverse events reported during the study.

This safety finding is considered significant given the history of the technology’s development. Verve Therapeutics, the original developer of the therapy, previously had to shelve its first gene-editing candidate due to safety concerns.

The successful safety and efficacy signals for VERVE-102 suggest a potential path forward for base-editing technologies in treating cardiovascular risk factors, though the therapy remains in the early stages of clinical testing.

Acquisition and Strategic Development

Eli Lilly integrated VERVE-102 into its portfolio following a $1 billion buyout of Verve Therapeutics, which was completed on June 17, 2025.

The acquisition reflects a broader pharmaceutical shift toward genetic medicines that can address the root cause of chronic conditions rather than managing symptoms through lifelong medication. By targeting the genetic drivers of cholesterol production, the therapy aims to eliminate the need for the continuous dosing associated with traditional lipid-lowering drugs.

The Role of LDL Cholesterol in Heart Disease

Low-density lipoprotein (LDL) cholesterol is a primary contributor to the development of atherosclerosis, a condition where plaque builds up inside the arteries. Over time, this buildup can narrow the arteries and restrict blood flow, potentially leading to heart attacks or strokes.

While medications such as statins and PCSK9 inhibitors are effective at lowering LDL levels, their efficacy depends heavily on patient adherence. Many patients struggle to maintain the strict regimens required by these conventional medicines, which can lead to fluctuating cholesterol levels and increased cardiovascular risk.

A one-time gene-editing intervention would theoretically remove the barrier of patient adherence by permanently altering the body’s ability to produce or process cholesterol, ensuring a consistent reduction in LDL levels without the need for ongoing pharmacy visits or daily pills.

Future Outlook and Limitations

Despite the encouraging 62% reduction in cholesterol observed in the high-dose group, the trial is still in Phase 1. Early-stage trials are primarily designed to assess safety and determine dosage; they are not large enough to definitively prove long-term efficacy or the overall impact on heart disease events.

Further research will be required to determine if the cholesterol reduction is sustained over several years and whether the treatment significantly reduces the incidence of heart attacks and strokes across a broader, more diverse patient population.

The reporting on these early results was first detailed by STAT.